BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 20, 2009
View Archived Issues
Peptimmune, Novartis Sign $500M Deal for MS Drug
Peptimmune Inc., a privately held U.S. biotechnology company, has granted Novartis AG an exclusive option to license its drug candidate for multiple sclerosis, PI-2301. (BioWorld Today)
Read More
Drop in Manufacturing Demand Prompts Cuts to XOMA's Staff
Read More
Will Health Care Reform Save Biotech, Economy
Read More
NewCo News: Carolus Therapeutics Wants to be King of Cytokine Targeting
Read More
Holiday Notice
Read More
Corrections & Clarifications
Read More
FDA Issues Final Guidance on Rules for GE Animals
Read More
Clinic Roundup
Read More
Other News To Note
Read More